Hormonal therapy is any treatment that adds, blocks, or removes hormones in the body to treat a medical condition. It spans several areas of medicine, from managing menopause symptoms and treating cancer to supporting gender transition and addressing conditions like polycystic ovary syndrome (PCOS). The common thread is using the body’s hormonal signaling system as a lever to produce a specific therapeutic effect.
How Hormonal Therapy Works
Hormones are chemical messengers that travel through the bloodstream and bind to receptors on cells, switching certain genes on or off. Hormonal therapy intervenes at one or more points in that chain. Some treatments supply hormones the body no longer makes in sufficient quantities. Others block hormones from reaching their receptors, effectively silencing the signal. A third approach stops hormone production altogether, either through medication or, in rare cases, surgery to remove a hormone-producing gland.
Because different tissues depend on different hormones, the specific drugs and strategies vary widely depending on the condition being treated. But the underlying logic is the same: change the hormonal environment, and you change what the cells do.
Menopause Hormone Therapy
The most familiar form of hormonal therapy is hormone replacement for menopause. As estrogen levels drop during menopause, many people experience hot flashes, vaginal dryness, urinary discomfort, and sleep disruption. Replacing estrogen relieves these symptoms, and randomized studies show that people who start hormone therapy within 10 years of menopause onset (generally before age 60) also see a reduction in bone fractures and overall mortality.
There are two broad categories. Systemic estrogen therapy delivers estrogen throughout the body via a pill, skin patch, gel, cream, spray, or ring. It treats the full range of menopause symptoms. Low-dose vaginal estrogen, available as a cream, tablet, or ring, targets only vaginal and urinary symptoms with much less estrogen absorbed into the bloodstream.
If you still have a uterus, estrogen is almost always paired with a progestogen. Taking estrogen alone can thicken the uterine lining and raise the risk of endometrial cancer. Adding a progestogen prevents that thickening. If your uterus has been removed, the progestogen component is typically unnecessary.
Choosing a Delivery Method
Patches are one of the most popular options for both patients and providers. They’re applied once or twice a week, depending on the prescription, and bypass the digestive system entirely, which can reduce certain risks. Oral pills have the longest track record of scientific data and offer convenience, especially in formulations that combine estrogen and progestogen in a single tablet. Topical gels, creams, and sprays are rubbed into the forearm or thigh, though absorption can be inconsistent, sometimes not delivering the full prescribed dose. Vaginal rings are typically replaced every three months, while other vaginal products often require daily or twice-weekly use.
Implanted pellets placed under the skin do exist but are not recommended by the Menopause Society or the Endocrine Society. They use compounded hormones that lack FDA approval, and once placed, a pellet cannot be removed. If you experience side effects or hormone levels spike too high, you simply have to wait three to four months for it to wear off.
Side Effects and Risks
Common side effects of estrogen include headaches, breast tenderness, nausea, mood changes, and leg cramps. Progestogen can cause similar symptoms along with spotting between periods, fatigue, dizziness, and acne. Most of these settle within the first few months as the body adjusts.
On the more serious end, menopause hormone therapy has been associated with a small increase in the risk of blood clots and breast cancer. High estrogen levels in particular may raise the chance of clots, stroke, or persistent breast tenderness. The FDA recently updated labeling on menopausal hormone therapy products, removing some of the most prominent boxed warnings around cardiovascular disease, breast cancer, and dementia after reviewing newer evidence. The risk profile depends heavily on age, timing, and delivery method.
Cancer Treatment
Hormonal therapy is a cornerstone of treatment for cancers that depend on hormones to grow, particularly breast cancer and prostate cancer. Rather than supplying hormones, this form of therapy starves the tumor of them.
Prostate Cancer
Normal and cancerous prostate cells both rely on androgens (primarily testosterone) to grow. Androgens bind to a receptor inside prostate cells, activating genes that tell the cell to multiply. Hormonal therapy for prostate cancer disrupts that process at different points.
The most common approach is androgen deprivation therapy, or ADT, which slashes the body’s testosterone production. Surgical removal of the testicles reduces blood testosterone by 90% to 95%. Medications that suppress signals from the pituitary gland achieve a similar effect without surgery. Anti-androgens take a different approach: instead of lowering testosterone levels, they block the androgen receptor so testosterone cannot activate it. A third class of drugs, androgen synthesis inhibitors, goes further by shutting down an enzyme required to produce testosterone not only in the testicles but also in the adrenal glands and in tumor tissue itself, lowering testosterone to a greater extent than any other known treatment.
Side effects across these therapies include hot flashes, loss of libido, erectile dysfunction, breast tenderness, and nausea. Some anti-androgens carry specific risks like liver damage or an increased chance of fractures and falls.
Breast Cancer
Many breast cancers are hormone receptor-positive, meaning they grow in response to estrogen. Treatment strategies mirror the logic used in prostate cancer: either block the receptor or cut off the hormone supply. Aromatase inhibitors, for instance, prevent the body from converting other hormones into estrogen, reducing estrogen levels dramatically. These therapies are often prescribed for years after initial treatment to lower the chance of recurrence.
Gender-Affirming Hormone Therapy
For transgender and gender-diverse individuals, hormonal therapy aligns physical characteristics with gender identity. Feminizing hormone therapy typically begins with a medication that suppresses testosterone’s effects, followed by estrogen starting about four to eight weeks later. Estrogen triggers the development of secondary sex characteristics associated with female puberty, such as breast growth, redistribution of body fat, and softening of the skin. At the same time, it slows or stops changes driven by testosterone.
Masculinizing hormone therapy centers on testosterone, which is most commonly delivered through the skin (gels or patches) rather than injections or pellets. Testosterone deepens the voice, increases muscle mass, stimulates facial and body hair growth, and redistributes fat.
Both types of gender-affirming therapy are long-term commitments. Some physical changes are reversible if therapy stops, but others, like voice deepening or breast development, are permanent.
Hormonal Therapy for PCOS
Polycystic ovary syndrome involves a hormonal imbalance that can cause irregular periods, excess androgen levels, and difficulty ovulating. Hormonal treatments here vary depending on the goal. For people trying to conceive, medications like letrozole help the body produce more of the hormones needed to trigger ovulation. Clomiphene is another option, sometimes paired with metformin (a diabetes drug that improves insulin sensitivity, since insulin resistance is common in PCOS). For those not trying to conceive, hormonal contraceptives are often used to regulate periods and reduce androgen-driven symptoms like acne and excess hair growth.
Monitoring During Treatment
Regardless of the reason for hormonal therapy, regular blood work helps confirm that hormone levels stay in a safe, effective range. Testing is generally recommended four to six weeks after starting therapy or changing a dose, then every six to twelve months once levels are stable. For menopausal hormone therapy, the target for estradiol (the primary form of estrogen) typically falls between 50 and 100 picograms per milliliter. Transgender women on feminizing therapy may target a higher range of 100 to 200 pg/mL.
If you still have a uterus and are taking estrogen, progesterone levels are also monitored to confirm adequate protection of the uterine lining. For prostate cancer patients on androgen deprivation, testosterone levels are tracked to verify they’ve dropped low enough to suppress tumor growth. These check-ins catch dosing problems early, before side effects or health risks have a chance to escalate.